Optimizing Imaging in ER-positive Metastatic Breast Cancer to Improve Clinical Outcomes

Gary Ulaner, MD, PhD and Jeremy Force, DO review estrogen receptor (ER)-positive breast cancer and the various strategies available for diagnosing estrogen receptor (ER)-positive breast cancer.

Experts provide an overview of the imaging modalities that can detect estrogen receptor status in patients with breast cancer.

Dr Gary Ulaner compares the role of FDG-PET and FES-PET imaging in ER+ Breast Cancer and the ability of each of the 2 techniques in assessing ER status.

Expert perspective on the applications of FES-PET imaging in treatment decision-making in patients with breast cancer.

A comprehensive analysis of the potential role of FES-PET imaging in assessing ER status in tumors that are difficult to biopsy and in evaluating the extent of disease.

Dr Jeremy Force illustrates how FES-PET aids in the care of patients with breast cancer through a clinical case.

Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.

Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.

Dr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.